What are the top 10 corporate VCs in biopharma today? And what do they want to fund — or steer clear of?
Corporate money from Big Pharma is bleeding into private equity deals at a rapid clip, now representing a huge chunk of the total cash pie doled out to biotech ventures each year. Their motivations have moved beyond stocking research-starved pipelines, instead moving into private finance because the ideas they stumble on can influence longterm strategy.
Plus, well… they could use the returns.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.